19:28 , Jul 3, 2018 |  BC Extra  |  Company News

Management tracks: Cigna, Novocure, Voyager

Health services company Cigna Corp. (NYSE:CI) appointed Mark McClellan to its board, effective the earlier of Dec. 1 or the close of Cigna's acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). McClellan is director of the...
18:58 , Mar 29, 2018 |  BC Innovations  |  Emerging Company Profile

Strengthening synapses

Syndesi Therapeutics S.A. is developing SV2A modulators to improve cognitive function in a range of indications including mild-to-moderate Alzheimer’s disease by regulating a broader sweep of neurotransmitters than available therapies. Cognitive impairment in AD stems...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Levetiracetam: Phase II data

AgeneBio Inc. , Carmel, Ind.   Product: Levetiracetam ( AGB101 )   Business: Neurology   Molecular target: Synaptic vesicle protein (SV2A)   Description: Low-dose formulation of levetiracetam, a high affinity synaptic vesicle protein (SV2A) ligand...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

AgeneBio board of directors update

AgeneBio Inc. , Carmel, Ind.   Business: Neurology   Appointed: Patrick LePore as chairman, formerly president, CEO and chairman of Par Pharmaceutical Cos. Inc.  ...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

AgeneBio management update

AgeneBio Inc. , Carmel, Ind.   Business: Neurology   Hired: Jerry McLaughlin as president and CEO, formerly SVP and chief commercial officer of NuPathe Inc. , which Teva Pharmaceutical Industries Ltd. acquired  ...
07:00 , May 24, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Not applicable A clinical study suggests epilepsy drugs could be useful for treating or preventing AD. In imaging studies, patients with amnestic...
07:00 , May 24, 2012 |  BC Innovations  |  Targets & Mechanisms

Cooling down AD

A team from The Johns Hopkins University has clinical proof of concept for an unconventional approach to slowing the progression of Alzheimer's disease-reducing activity in the hippocampus with antiepileptic drugs. 1 Based on the findings,...
07:00 , May 31, 2010 |  BC Week In Review  |  Financial News

AgeneBio completes venture financing

AgeneBio Inc. , Indianapolis, Ind.   Business: Neurology   Date completed: 5/12/10   Type: Venture financing   Raised: $300,000   Investors: Indiana Seed Fund I  ...